Drugs / Esflurbiprofen
Esflurbiprofen
also known as
EFTS · TK-254RX · BTS 24332 · Esflurbiprofen Topical System · Esflurbiprofene · Esflurbiprofeno
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT07307794 | Jan → Mar 2026 overdue | — | Teikoku Seiyaku Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT06870422 | Feb → Apr 2025 | — | Teikoku Seiyaku Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06823284 | Jan → Feb 2025 | — | Teikoku Seiyaku Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06042192 | Sep → Nov 2023 | — | Teikoku Seiyaku Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04908748 | May → Nov 2021 | — | Teikoku Seiyaku Co., Ltd. | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT06866613 | Mar → Oct 2025 | — | Teikoku Seiyaku Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT06871046 | Feb → Sep 2025 | — | Teikoku Seiyaku Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT03434197 | Feb 2018 → Jan 2021 | osteoarthritis, knee | Taisho Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02729207 Comparator | Jul → Dec 2016 | — | Teikoku Seiyaku Co., Ltd. | Terminated | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Esflurbiprofen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06823284 ↗ |
| Known as | BTS 24332 | ChEMBL registry synonym — accepted as the source's own label CHEMBL435298 ↗ |
| Known as | EFTS | “Characterisation of Adhesion Performance of a Newly Developed Esflurbiprofen Topical System (EFTS) - a Phase I, Open-label Study in Healthy Subjects.” NCT07307794 ↗2“Esflurbiprofen Topical System (EFTS)” NCT06871046 ↗ “Esflurbiprofen Topical System (EFTS)” NCT06866613 ↗ |
| Known as | Esflurbiprofen Topical System | “Esflurbiprofen Topical System (EFTS)” NCT06866613 ↗ |
| Known as | Esflurbiprofene | ChEMBL registry synonym — accepted as the source's own label CHEMBL435298 ↗ |
| Known as | Esflurbiprofeno | ChEMBL registry synonym — accepted as the source's own label CHEMBL435298 ↗ |
| Known as | TK-254RX | “TK-254RX will be applied with no special condition” NCT06870422 ↗ |
| Action | Inhibit | “Esflurbiprofen is a cyclooxygenase (COX) inhibitor” NCT04908748 ↗ |
| Modality | Small molecule | — CHEMBL435298 ↗ |
| Route | Topical | “A plaster containing 40 mg of Esflurbiprofen and 36.2 mg of Japanese Pharmacopoeia mentha oil per patch (10 × 14 cm)” NCT03434197 ↗ |